3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
pembrolizumab
213
Cyclophosphamide
123
Nivolumab
110
Carboplatin
94
fludarabine
81
Gemcitabine
78
Specimen Handling
74
Bevacizumab
73
Injections
71
venetoclax
70
Magnetic Resonance Spectroscopy
67
Dexamethasone
66
Paclitaxel
64
Biopsy
59
atezolizumab
56
Cisplatin
54
Ipilimumab
50
Temozolomide
46
Lenalidomide
43
Azacitidine
43
Docetaxel
42
Pemetrexed
41
Rituximab
40
Radiotherapy
40
Oxaliplatin
40
Fluorouracil
39
Cetuximab
38
durvalumab
37
Cytarabine
36
Capecitabine
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Histamine H2 Antagonists
×
1 year
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled